About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
S
2020 ASCO Update on MBC: Does Removal of Primary Breast Cancer Impact OS and QoL?
By
Sara Robinson
3 Videos
660 views
October 5, 2020
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
London Breast Meeting
London Breast Meeting 2024
Wed, Sep 4, 2024
12:35
Insights from 2023 SABCS
SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…
Feat.
S. Tolaney,
H. Rugo
17:20
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…
Feat.
P. Tarantino
04:28
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant …
Feat.
S. Tolaney
49:07
SABCS 2022 Conference Coverage
SABCS 2022 Expert Panel Discussion: Practice-Changing Updates
Feat.
J. O'Shaughnessy,
S. Tolaney,
S. Hurvitz,
H. Rugo
07:50
Oncology Data Advisor
ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…
Feat.
K. Kalinsky
50:59
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Panel Discussion: "Early Stage Breast Cancer"
Feat.
S. Tolaney,
H. Rugo
17:35
Insights from 2023 SABCS
SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…
Feat.
P. Tarantino
14:59
Insights from 2023 SABCS
SABCS 2023 Insights: "NRG Oncology/NSABP B-51/RTOG 1304 Trial -…
Feat.
T. Mamounas
21:37
Dana-Farber Cancer Institute
Standard Treatments for HR+/HER2- mBC in 2023
Feat.
S. Sammons
03:24
ecancer
SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…
Feat.
V. Kaklamani
20:42
Total Health
2022 Updates in TNBC
Feat.
I. Schlam
13:23
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Summary: "A Pooled Analysis of T-DXd for HER2+ mBC Wi…
Feat.
S. Hurvitz
20:16
University of Colorado Cancer Center
Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…
Feat.
V. Borges
09:14
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "Omission of Breast Surgery After Neoadjuva…
Feat.
H. Kuerer
12:24
Stanford Medicine
HR+ mBC: CDK4/6i Progression Management
Feat.
M. Dolezal
11:19
Adam Brufsky
HER2+ mBC: The Role of TDM-1
13:32
13th Annual Winter Breast Cancer Symposium
2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs
Feat.
W. Gradishar
08:48
James Martin
2L Therapy for ER+ mBC Following CDK4/6i
08:54
Insights from 2023 SABCS
SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for Pat…
Feat.
S. Tolaney,
H. Rugo
14:54
Grace Choong
Resistance Mutations in HR+ mBC After 1L ET + CDK4/6i: Next Lines an…
